Corporate Clinical Development  
CCD -5115.T01 Protocol Template  
Revision 05  
     
 
Page 1 of 36 
BD Protocol #:  DBC -18PENDL01  
Protocol Title : Comparative User Experiences with BD Nano™ PRO  
32G Extra Thin Wall Pen Needle vs the Terumo  
Nanopass® 34G Pen Needle  
 
Current Version  Version 4.0 25Feb2019  
Version  History  Version 1.0 05Dec2018 (Original ) 
Version 2.0 19Dec2018  
Version 3.0 06Feb2019  (Site specific amendment)  
Sponsor  Becton, Dickinson, and Company  
BD Medical – Diabetes Care  
[ADDRESS_995127]  
Franklin Lakes, NJ [ZIP_CODE]  
Sponsor Medical 
Monitor  
 Stanislav Glezer, MD ,  
Worldwide V P, Medical Affairs  
BD Diabetes Care  
Office #: 201 .847.5214  
Mobile #: [PHONE_7606]  
Sponsor  
Risk Assessment    Signif icant Risk (SR)                  Non-significant Risk (NSR)  
                                                      Minimal Risk  
 
The product information and data disclosed through this protocol are confidential and may 
not be disclosed without prior written consent of Becton, Dickinson and Company.  
This study will be performed in accordance with all stipulations of the protocol and in 
compliance with all applicable BD Policies and Procedures.  This study will be conducted in 
accordance with the ethical principles that originate from the Decl aration of Helsinki and the 
Belmont Report. Study conduct will comply with US FDA Regulations, applicable state and 
local regulations, and the Good Clinical Practice guidelines set forth by [CONTACT_189900] (ICH -E6) and ISO1415 5.  
  
Protocol Number: DBC –18PENDL01  
Version 4.0 25Feb2019  
 
 
BD CONFIDENTIAL    Page 2 of 36 
SPONSOR PROTOCOL APPROVAL  
 
Signature [CONTACT_225456].  
Individual or 
function  Name  [CONTACT_728678] , 
PharmD  This document is signed 
electronically in the 
eTMF system   
Medical Monitor  Stanislav Glezer, 
MD This document is signed 
electronically in the 
eTMF system   
Study Statistician  Julie Berube , PhD  This document is signed 
electronically in the 
eTMF system   
Study Manager  Jonathan 
Washington  This document is signed 
electronically in the 
eTMF system   
 
Protocol Number: DBC –18PENDL01  
Version 4.[ADDRESS_995128] this study in accordance with all stipulations of 
the protocol and in compliance with all applicable Good Clinical Practices and regulations.  
 
 
              
Signature [CONTACT_789]      [INVESTIGATOR_225423]: DBC –18PENDL01  
Version 4.[ADDRESS_995129] OF ABBREVIATION S AND DEFINITION OF TERMS  ................................ ...........  7 
1.0 INTRODUCTION  ................................ ................................ ................................ ...... 8 
2.0 OBJECTIVES  ................................ ................................ ................................ ...........  8 
 Primary Objective  ................................ ................................ ................................ .........  8 
 Secondary Objectives  ................................ ................................ ................................ ... 9 
 Explorator y Objectives  ................................ ................................ ................................ .. 9 
3.0 STUDY DESIGN  ................................ ................................ ................................ ...... 9 
 Overall Study Design  ................................ ................................ ................................ .... 9 
 Specificat ion of Study Endpoints  ................................ ................................ ................  10 
3.2.1 Primary Endpoints  ................................ ................................ .......................  10 
3.2.2 Secondary Endpoints ................................ ................................ ...................  10 
3.2.3 Explor atory Endpoints  ................................ ................................ .................  10 
3.2.4 Safety Endpoints  ................................ ................................ ..........................  11 
 Acceptance Criteria  ................................ ................................ ................................ .... 11 
 Treatment Allocation and Methods to Reduce Bias  ................................ ...................  12 
3.4.1 Randomization  ................................ ................................ .............................  12 
3.4.2 Masking/Blinding  ................................ ................................ ..........................  [ADDRESS_995130] Labeling  ................................ ................................ ................................ .........  15 
 Maintenance and Storage of Study Products  ................................ ............................  16 
6.0 STUDY METHODS  ................................ ................................ ................................  16 
 Screening and Enrollment  ................................ ................................ ..........................  16 
6.1.1  Demo graphics/Diabetes History  ................................ ..............................  16 
6.1.2  Visual Inspection of Injection Site  ................................ ...........................  16 
6.1.3  Proficiency  ................................ ................................ ................................ .. 17 
6.1.4  Randomization  ................................ ................................ ...........................  17 
 Study Procedures  ................................ ................................ ................................ ....... 17 
6.2.1 Injections  ................................ ................................ ................................ ...... 17 
Immediately after each  injection the following evaluation will be performed:  ...... 18 
After each pair of injections  ................................ ................................ ..................  18 
After all injections completed  ................................ ................................ ................  18 
 End of Visit and Study Completion  ................................ ................................ .............  19 
7.0 INTERRUPTION OR DISC ONTINUATION OF PARTI CIPATION/TESTING  ..........  19 
Protocol Number: DBC –18PENDL01  
Version 4.0 25Feb2019  
 
 
BD CONFIDENTIAL    Page 5 of 36 
 Discontinuation of Study Subjects  ................................ ................................ ..............  19 
 Discontinuation Visits and Follow -up Procedures  ................................ ......................  19 
 Replacement of Discontinued Subjects/Specimens  ................................ ..................  19 
 Retention of Data from Discontinued Subjects/Specimens  ................................ ....... 19 
8.0 RISK / BENEFIT ASSES SMENT  ................................ ................................ ............  20 
 Potential Risks  ................................ ................................ ................................ ............  20 
 Potential Benefits  ................................ ................................ ................................ ........  20 
9.0 SAFETY  ................................ ................................ ................................ .................  20 
 Adverse Event Definitions  ................................ ................................ ..........................  20 
 Adverse Event (AE) Management  ................................ ................................ ..............  21 
 Assessment of Adverse Events (AEs)  ................................ ................................ ....... 21 
 Additional Procedures for Assessing & Reporting Serious Adverse Events (SAE)  .. 22 
9.4.1 Reporting Obligations to IRB/EC and Health Authorities  ............................  [ADDRESS_995131]  ................................ ........  24 
 Defective or Failed Study Products  ................................ ................................ ..........  24 
12.0 DATA COLLECTION AND MANAGEMENT  ................................ .........................  24 
 Source Documents  ................................ ................................ ................................ ... 24 
 Case Report Forms (CRF)  ................................ ................................ .......................  25 
12.2.1 CRF as Source Document ................................ ................................ .........  25 
12.2.2 C RF/Data Transmittal  ................................ ................................ ................  25 
 Data Management and Storage  ................................ ................................ ...............  25 
13.0 STATISTICAL METHODS  ................................ ................................ ....................  26 
 Sample Si ze Determination  ................................ ................................ ......................  26 
 Data Evaluability  ................................ ................................ ................................ ....... 26 
 Statistical Methods  ................................ ................................ ................................ .... 26 
 Demograph ics/Other descriptive information  ................................ ...........................  27 
 Safety Analysis  ................................ ................................ ................................ .........  27 
 Interim analysis  ................................ ................................ ................................ .........  27 
 Additional analyses  ................................ ................................ ................................ ... 28 
14.0 QUALITY C ONTROL AND ASSURANCE  ................................ ............................  28 
 Accountability of Study Products  ................................ ................................ ..............  28 
 Monitoring  ................................ ................................ ................................ .................  28 
 Audits and Inspec tions  ................................ ................................ .............................  28 
 Protocol Deviations  ................................ ................................ ................................ ... 29 
15.0 ETHICAL AND REGULATO RY STANDARDS  ................................ .....................  29 
 IRB/EC  ................................ ................................ ................................ ......................  29 
 Informed Consent  ................................ ................................ ................................ ..... 29 
 Confidentiality of Data ................................ ................................ ...............................  29 
 Proto col Modifications ................................ ................................ ...............................  30 
 Study Discontinuation  ................................ ................................ ...............................  30 
 Clinical Study Registration  ................................ ................................ ........................  30 
Protocol Number: DBC –18PENDL01  
Version 4.0 25Feb2019  
 
 
BD CONFIDENTIAL    Page 6 of 36 
 Publication of Results  ................................ ................................ ...............................  31 
 Recor d Retention  ................................ ................................ ................................ ...... 31 
16.0 BIBLIOGRAPHY/REFEREN CES ................................ ................................ .........  31 
17.0 PROTOCOL REVISION HI STORY  ................................ ................................ ...... 32 
18.0 APPENDICES  ................................ ................................ ................................ ...... 34 
18.1: Gravimetric Leakage Quantification Procedure  ................................ ......................  34 
 Needle Bending Evaluation  ................................ ................................ ......................  35 
18.3 Pen  Cleaning Procedure  ................................ ................................ ..........................  36 
 
  
Protocol Number: DBC –18PENDL01  
Version 4.[ADDRESS_995132] OF ABBREVIATION S AND DEFINITION OF TE RMS  
AE Adverse Event 
AUC  Area Under Curve  
BD Becton, Dickinson and Company  
BG Blood Glucose  
BMI Body Mass Index  
cat Catalog  
CFR Code of Federal Regulations  
CI Confidence Interval  
CRF Case Report/Record Form  
cm Centimeter  
DFSP  Defective or Failed Study Product  
EDC  Electronic Data Capture  
FDA Food and Drug Administration  
FDAAA  FDA Amendments Act of [ADDRESS_995133]  
HCP  Healthcare Practitioner  
ICH International Conference on Harmonization  
ICMJE  International Committee of Medical Journal Editors  
INJ Injection  
IRB/EC  Institutional or Independent Review Board/Ethics Committee  
lpf Injection Peak Forces  
mm Millimeter  
NDC  National Drug Code  
NI Non-inferiority  
PHI Protected Health Information  
PI [INVESTIGATOR_368338]: DBC –18PENDL01  
Version 4.[ADDRESS_995134] launched 
similar length pen needles with thinner gauge ne edles, such as 33G and 34G . 
Previous studies reported ethnic differences in pain perception (primary study outcome).1 More 
specifically, Asian subjects compared to other ethnicities demonstrated lower pain thresholds 
and greater pain sensitivity.2, 3, 4, 5  The continuous development of thinner needles is focused on 
the improvement of the injection comfort through the reduction in pain sensation.   It is not clear 
if the difference in needle gauge beyond 32G, is associated with clinically meaningful changes 
in pain sensation. BD is conducting several studies in different ethnic and geographic populations 
to address this question.   Data from this study is intended to support appropriate clinical decision 
making in choosing insulin pen needles in the [LOCATION_003], Japan and other countries.  
The comparative pen needle – Terumo Nanopass – although not commercially available in the 
US, presents the most relevant opportunity for comparison of needles of different gauge. The 
availability of such device in Japan, makes the choi ce of Japanese American patients logical 
from the perspective of eventual results generalizability, not only in the [LOCATION_003], but also in Japan 
and other countries. Differences in user experience and clinical outcomes may not be limited to 
pain sensation, but a lso by [CONTACT_728670].   If a patient does not change 
force, dose delivery with the thinner needle will require more time.   Besides a potential  negative 
user experience (more force) this may lead to more insulin leakage from both needle tip and 
insertion site (more time) resulting in incomplete insulin dose delivery.   This may directly impact 
glycemic control.  
The intent of this comparative use s tudy is to determine whether Japanese American patients’ 
experiences are different when using the BD Nano™ PRO 4mm x 32G extra thin wall, 5 -bevel 
pen needle (herein referred to as BD Nano™ PRO) vs the Terumo Nanopass® 4mm x 34G 
(thinner gauge) pen needle ( herein referred to as Terumo Nanopass®).   These experiences 
include the perceived force to deliver dose, the ability to deliver the full dose (measured by 
[CONTACT_185828]), injection pain and bending.  
 
 
2.0 OBJECTIVES  
 Primary  Objective  
Demonstrate non -inferiority of the BD Nano ™ PRO  pen needle compared to the Terumo  
Nanopass® pen needle for i njection pain.  
 
Protocol Number: DBC –18PENDL01  
Version 4.0 25Feb2019  
 
 
BD CONFIDENTIAL    Page 9 of 36 
 Secondary Objectives  
Demonstrate superiority of BD Nano™ PRO  vs Terumo Nanopass ® pen needle  for the 
following:  
 Leakage from the need le tip and the injection site (measurements combined) after 
removal  from body  
 Subject  perceived  force requ ired to deliver  dose  
 Patient  end needle bending after removal from body  
 If primary outcome demonstrates non -inferiority , then eval uate for superiority of 
Nano ™ PRO  vs Terumo Nanopass ®  
 
 Exploratory Objectives  
Compare BD Nano™ PRO vs Terumo Nanopass ® for the following : 
 Injection time  
 Patient  end needle breaking at any time  
 Survey responses pertaining to subjective assessments of pen needle characteristics  
3.[ADDRESS_995135] partially blinded, block randomized, prospective, single -visit, multi -center  
study to compare user experiences with BD Nano ™ PRO pen needle vs.  the thinner 
commercially available Terumo Nanopass®  pen needle . The study will include a minimum of 
[ADDRESS_995136] s via a reusable insulin pen device . All pen needles 
will be attached by [CONTACT_368352].  Subjects are to perform 12 injections  into the abdomen  (6 pairs of injections ). 
Pairs o f injections will be evaluated  and each  pair will contain one BD Nano ™ PRO  and one 
Terumo Nanopass®  pen needle . 
Subjects will not see pen needle labels or be informed which pen needle is being used to 
inject.  The BD Nano™ PRO  has a distinct configuration and subjects will most likely notice 
the difference vs the Terumo Nanopass® .  Subje cts will not be informed of the Terumo 
Nanopass® brand, length or gauge.  
The pen needle order within the pairs of injection s will be randomized  for each s ubject  and 
the pairs will be randomized to various abdominal injection sites  within each subject .  
Besides being informed of the requirement to insert the pen needles ‘straight -in’ 
(perpendicular), subjects will be instructed to use their usual injection technique . 
Protocol Number: DBC –18PENDL01  
Version 4.0 25Feb2019  
 
 
BD CONFIDENTIAL    Page 10 of 36 
 Specification of Study Endpoints  
3.2.1  Primary Endpoints  
 Injection Pain  
o Each Subject  will evaluate pain after completion of each pair of injections 
using a 15  cm relative Visual Analog Scale (VAS) .   
3.2.2  Secondary Endpoints  
 After each injection:  
o Leakage   
 After saline delivery equivalent to 30U of U100 insulin (0.3mL) 
and Subject  removal of pen needle from body, Study Staff will 
use the provided materials and scale to absorb leakage from the 
pen needle tip and injection site to measure the amount of 
leakage.  
 Leakage will be considered to be present if measurement is 
equivalent to  or greater than  5% of dose ( equivalent to or greater 
than 1.5U  of U100 insulin  – equivalent to ≥0.01 5g) 
o Bending  – patient -end cannula  
 Study Staff will use a provided needle  bend sca le and visually 
inspect  pen needles to determine the presence  of bending .  If 
present, study staff will determine and document degree of bend 
with the provided scale . For the purpose of answering the study 
objective,  needle bend will be considered >2 on the bend rating 
scale.  
 After each pair of injections : 
o Injection  force  
 Each Subject  will evaluate perceived injection  force after each 
pair of injections using a 5-point Likert scale (from 1st injection 
required much less force to deliver medication to 2nd injection 
required much less force to deliver medication ). 
Which pen needle required less force or effort to deliver the dose ? 
1st injection 
significantly  
less force or 
effort  1st injection 
slightly less 
force or 
effort  Both 
injections 
about the 
same  2nd injection 
slightly less 
force or effort  2nd injection 
significantly  
less force or 
effort  
 
3.2.3  Exploratory Endpoints  
 During each injection:  
Injection time – includes the following time periods for each injection  
Protocol Number: DBC –18PENDL01  
Version 4.0 25Feb2019  
 
 
BD CONFIDENTIAL    Page 11 of 36 
1) Time from when subject 1st pushes injection  button to time button fully 
depressed  
2) Time from when injection  button fully depressed to when pen needle 
removed from body  
3) Total injection time – the 2 time periods above combined   
 After each injection :  
o Breaking  
 Study Staff will record any patient end needle  breakage .  
Breakage is defined a s the patient -end metal cannula separated 
into two pi[INVESTIGATOR_6928] . 
 After all injections completed : 
o Survey responses  
 Subject  completes the following 5-point Likert scale survey 
(from Disagree to Agree ).  Subject  will be instructed to respond 
to the questions based on their usual (in -home use) injection 
experience.  Subject responses to survey questions  will be 
tallied . 
 
Disagree   
Somewhat 
Disagree   
Neutral   
Somewhat 
Agree   
Agree  
 
 Injection pain affects my level of satisfaction with my 
treatment.  
 Injection pressure needed to deliver the dose affects my level 
of satisfaction with my treatment.  
 Post injection leakage increases my level of concern that I 
may not be receiving my full dose of medication.  
 A bent needle increases my level of concern about the 
reliability of my injection.  
3.2.4  Safety Endpoints  
 Occurrence of adverse events will be evaluated, recorded, and followed up as 
required.  
 Acceptance Criteria  
Primary Objective:   
o BD Nano™ PRO  non-inferior to Terumo Nanopass ® for injection pain with 
partially blinded injections based on relative VAS , where -75mm indicates  
Protocol Number: DBC –18PENDL01  
Version 4.0 25Feb2019  
 
 
BD CONFIDENTIAL    Page 12 of 36 
worse pain for BD Nano ™ PRO  and +75mm indicates worse pain for Terumo 
Nanopass ® with a non -inferiority criterion of -10mm.     
 
Secondary Objective :   
o The BD Nano™ PRO  will be evaluated for superiority vs Terumo Nanopass ® 
for leakage, injection  force, and bending.   
o If the BD Nano™ PRO  demonstrates non -inferiority for injection pai n for the 
Primary Objective, compare the BD Nano™ PRO  vs Terumo Nanopass®  for 
superiority.   
 
Exploratory Objectives:  
o No formal acceptance criteri on has been established for the following 
objectives : time to deliver dose, dwell time, and survey responses  after all 
injections completed .  
 
 Treatment Allocation and Methods to Reduce Bias   
3.4.[ADDRESS_995137] 
in complying with site randomization.  
3.4.2  Masking/Blinding  
Subject s will be blinded to pen needle randomization, order of pairing, and will not be 
informed of needle type.  Since the BD Nano ™ PRO  and the Terumo Nanopass ® are 
designed differently, subjects will be aware which pen needle type is being used , but not 
the brand or needle gauge.  
3.4.[ADDRESS_995138], subjects will be required to perform t hree ‘straight in ’ 
(perpendicular)  injections in addition to other required tasks in order to take part in the 
study injections.  
 Stoppi[INVESTIGATOR_368339].  The Principal Investigator 
[INVESTIGATOR_53470] f or suspending study enrollment for reasons of Subject /Clinician safety and well -
being.  
4.[ADDRESS_995139] s with Type 1 or Type 2 diabetes 
who use an injection  pen system to deliver their insulin  and/or Victoza . A minimum of [ADDRESS_995140] one  parent or one grandparent 
born in Japan.  
Protocol Number: DBC –18PENDL01  
Version 4.0 25Feb2019  
 
 
BD CONFIDENTIAL    Page 13 of 36 
 Inclusion Criteri a 
Male and female patients will be considered for participation in the study if they fulfill the following 
conditions:  
a. Self-attesting Japanese American a dults 18 to  75 years of age ( inclusive)  
b. Self-attest to Japanese descent  
c. Diagnosed with Type 1 or Type 2 diabetes  
d. Self-injecting  using an  injection  pen for ≥3 months  with any pen needle  
e. Injecting a min imum of  ≥10 units of insulin  and/or Victoza at least once per day  
f. Able to demonstrate proficiency  using an injection  pen into an injection model  
f. Able and willing to provide i nformed consent  
g. Able and willing to complete all study procedures  
 
 Exclusion Criteria  
Subject s with any one of the following characteristics will be excluded from participation in this 
study:  
a. Not s elf-injecting  (for example injections completed by a family member)  
b. Self-injecting with a pen injector for less than [ADDRESS_995141] hair at the injection area reduced with an electric razor if it is 
determined the hair will interfere with leakage evaluation  
e. Failure to confirm which pen needle (gauge and needle length) subject is currently 
using.  To confirm, subject may be asked to bring their pen and pen needles to the 
site or site staff  may confirm via medical record or pharmacy.  
f. Pregnant  (self-attestation )   
g. Curren tly taking anti -platelet  or anticoagulant  therapy  (up to 162 mg per day of 
aspi[INVESTIGATOR_103011]).  
h. History of a bleeding disorder  
i. History of recurrent dermatological conditions or skin disorder (e.g., psoriasis, 
eczema)   
j. Gross skin anomalies and abnormalities located at or very c lose to the injection sites  
that would significantly limit available injection space .  
k. History of symptomatic low blood pressure or history of fainting (syncope) during 
hypodermic injections   
l. Use of any analgesic medica tions  within [ADDRESS_995142] study  injection, and during 
the study  (up to 162 mg per day of aspi[INVESTIGATOR_103011]).  
Protocol Number: DBC –18PENDL01  
Version 4.[ADDRESS_995143] the patient at risk or make them unable to perform study 
procedures or has the potential to confound interpretation of the study results  
n. Currently participating in another pen needle study  
o. Employed by, or currently serving as a contractor or consultant to BD or any  diabetes 
injectable medication , injection pen, or  pen needle manufacturer  
5.0 DESCRIPTION OF STUDY  PRODUCTS  
Pen needles are a component of pen -based injection systems routinely utilized for parenteral 
administration of medica tions  such as insulin. A pen needle consists of a doubled ended cannula that is 
asse mbled into an injection -molded plastic hub using adhesive. The hub has threads, which allow it to 
be screwed onto the pen -injector device. This allows the Non-Patient  (NP) end of the needle  to penetrate 
through the rubber septum of the pen cartridge to create the fluid flow path. The pen needle device 
interfaces with the delivery site providing a conduit for delivery into the subcutaneous tissue space. Pen 
needles will be attached and primed per manufacturer’s instructions with 0.9% sterile saline. A new pen 
needle will be utilized for each injection . 
 
 Test Product  
 BD Nano™ PRO 4mm x  32G XTW 5-bevel pen needle  
 The BD pen needle to be used in this study has a 32G extra -thin walled 
cannula with a nominal length of 4mm, and a [ADDRESS_995144]  
 Terumo Nanopass ® 4mm x 34G   
 The Terumo Nanopass will be labeled  “For Investigational  Use Only” as 
this product is not currently available for sale in t he US. 
 Ancillary  Products  
 [COMPANY_011] ClikSTAR® Insulin Reusable Pen  
Note: Either a new or cleaned ClikSTAR® Insulin Reusable Pen will be used for 
each subject depending on site  preference . See Appendix 18.3 for Pen Cleaning 
Procedure).  
 Pen needles (for pen/pen needle proficiency evaluation)  
 Pen needle removal fixtures  
 Electric shaver/r azor (if injection area has excessive hair that will interfere with 
leakage evaluation)  
 Antiseptic pads  
 Bandages   
 Analytical Scale  and required ancillary scale supplies  (e.g. marble slab,  calibrated 
weight)  
 Injection Pads  
 Cellulose Spears   
 Plastic Falcon Tubes  
 3mL 0.9% Sodium Chloride Injection  Cartridges  
Protocol Number: DBC –18PENDL01  
Version 4.0 25Feb2019  
 
 
BD CONFIDENTIAL    Page 15 of 36 
0.9% Sodium C hloride Injection, (Mfd for Becton Dickinson by [CONTACT_368353], Bloomington, IN, [LOCATION_003]).  
 
Placebo Injection Solution: 0.9% Sodium Chloride Injection, 3cc Cartridge. The sterile 
0.9% saline cartridges were aseptically manufactured and filled by [CONTACT_728671]. The cartridges met 
all performance requirements, including toxicology and sterility acceptance criteria, 
outlined in the BD Standardized Cartridge Specification. The sterile 0.9% saline 
cartridges will be inserted into commercially available pen systems to provide the 
necessary placebo reservoir.  
 
Note: New pen cartridges will be utilized for each subject and will not be reused 
between subjects.  
 
 Product Labeling  
Investigational devices (or the immediate packaging) shall be labeled in accordance with 
regulatory requirements, including the following statement: “CAUTION -Investigational device. 
Limited by [CONTACT_4496] (or [LOCATION_002]) law to investigational use. ” The BD Nano™ PRO unit label, 
at minimum on its immediate package , must indicate “For Investigational Use only”, with full 
statement on the outer packaging.   The Terumo Nanopass ®, must also indicate “For 
Investigational Use only”, with full statement on the outer packaging.  Refer to Study Supply Plan 
for further details on labeling requirements  and saline cartridges process/certification .  
For BD Nano™ PRO investigational products, box labeling will also include at a mini mum:  
o Product Identification  
o Manufacture name [CONTACT_225458]  
o EWO/Batch#  
o Use by/expi[INVESTIGATOR_320]  
o Sterility Claim (sterile or non -sterile)  
o “For Investigational Use only”  
 
Saline Cartridge Label Content  
 

Protocol Number: DBC –18PENDL01  
Version 4.0 25Feb2019  
 
 
BD CONFIDENTIAL    Page 16 of 36 
All other a ncillary p roducts will be supplied as labeled by [CONTACT_3455].   
 Maintenance and Storage of Study Products  
All study products  will be stored according to the manufactu rer’s instructions .  Refer to section 
11.[ADDRESS_995145] disposition during the study and 
upon study completion (e.g., disposal, return or destruction, defective products).  
6.0 STUDY METHODS  
 Screening and Enrol lment  
Befor e study start, investigational Site will  ensure the following : 
1. Analytical scales for leakage assessment are set up and calibrated  by [CONTACT_21724] . 
2. All Study Staff assigned to the following specific tasks will be trained and demonstrate 
proficiency with procedure : 
a. Set up pen/pen needle system  
b. Timing injection duration  
c. Leakage measurements  
d. Measure  needle bend  
e. Needle removal  
 
If site cannot confirm which pen and pen needle (gauge and length) the subject is currently using, 
the subject must  bring their injection  delivery system (s) (pen and pen needle ) with them to the 
Site. Subjects will also be asked to wear comfortable clothes to the Site on study day to enable 
easy accessibility to injection site area.  
 
Prior to study participation, every potential Subject must provide  written informed consent  and will 
be assigned a Subject number . After being presented with an overview of the study procedures, 
each Subject will be given ample time to review the consent form and ask any questions about 
the procedures.  If the Subject agrees to participate in the study he or she will sign the Informed 
Consent.  
This study requires one subject visit of approximately 60-[ADDRESS_995146] meets the eligibility requirements.  
6.1.1  Demographics/ Diabetes History  
Subject s will be asked a number of background and demographic questions to ensure 
they meet the study -specific eligibility criteria. The PI [INVESTIGATOR_368341] -reported by [CONTACT_31388] ; this information will be recorded  in the 
source documents. Information collected will include, but is not limited to age, gender , 
ethnicity  and diabetes history ( Type 1 or Type 2  diabetes , current injection therapy, current 
pen needle, typi[INVESTIGATOR_368342](s) ).   
6.1.2  Visual Inspection of In jection Site  
A visual assessment of the injection site area will be performed to determine if any obvious 
skin anomalies or imperfections that would significantly limit available injection sites, ( e.g. 
redness, swelling, moles, marks, bruises, cuts, abrasi ons, discoloration, tattoos, masses , 
Protocol Number: DBC –18PENDL01  
Version 4.0 25Feb2019  
 
 
BD CONFIDENTIAL    Page 17 of 36 
lipohypertrophy  and or an y other abnormalities).  Study S taff will determine if the hair at 
the injection sites will need to be removed ( with provided electric s haver ) prior to injections . 
Note: excessive hair must be removed to allow measurements of leakage.  
6.1.[ADDRESS_995147] achieved 3 proper injections (e.g . injection 
‘straight in ’ (perpendicular) ) in addition to other tasks listed in the proficiency checklist . 
With a pen needle pre -attached and primed by [CONTACT_127009], the Study Staff will use a 
chec klist to determine successful proficiency of the Subject  to perform an injection using 
the ClikSTAR  Pen. If the Subject  is unable to demonstrate  proficiency, s/he will be 
discontinued from the study.   
6.1.[ADDRESS_995148]  will be assigned a randomization 
number . 
 
 Study Procedures  
6.2.1  Injections  
 Subjects will be informed that “these pen needles are to be inserted ‘straight -in” 
(perpendicular) Subjects will be provided with an Insulin Reusable Pen  with saline 
cartridges in place and the pen needles attached, primed, and set to 30U.   (A 
new ClikSTAR® Insulin Reusable Pen will be used for each subject at specific sites; 
subjects at remaining sites may use a new or cleaned ClikSTAR ® Insulin Reusable 
Pen).   
 Each injection pair will include:  
o 1 pen with the BD Nano™ PRO pen needle  
o 1 pen with the Terumo Nanopass® pen needle   
 Using their usual injecti on technique, Subject s will  inject saline with 
the pair of pens into their abdomen  per Study Staff instruction  and 
according to the randomization schedule .  
 If subject inserts at an acute angle or uses a skin pi[INVESTIGATOR_368343] , it is 
allowable under this study protocol but  should document ed on the 
study source . 
o The location of the injection sites wi ll be randomized   
o Each injection  will be  at least 1 inch from the previous injection  
 
 During needle injection , Study Staff will record two times:  
o From initial pressing of injection  button  (dose set knob) , to button fully 
depressed   
o From initial pressing of  injection button to the removal of the needle from body   
Protocol Number: DBC –18PENDL01  
Version 4.0 25Feb2019  
 
 
BD CONFIDENTIAL    Page 18 of 36 
Immediately after each injection the followi ng evaluation will be performed:   
 Study Staff will use the provided materials and scale to absorb leakage from the pen  
needle tip and injection site to me asure the amount of leakage  (refer to Appendix 18.1  
for leakage measurement procedure) . If any bleeding is observed, this will be noted 
and leakage measurement will  only be collected from the pen needle tip.    Leakage 
measurement  amounts will not be discussed in the presence of the Subject.  
 Study Staff will visually inspect each needle for the p resence of  bending and/or 
breakage .  If no bending is visually observed, Site Staff will record a  score of  “0” and 
the pen/needle  will be placed in the pen needle disposal fixture .   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 If bending  is visually observed, the pen/ pen needle will be placed on the bend scale  
(refer to Appendix 18.2).  The degree of bending will be assessed and scoring 
recorded by  [CONTACT_127009].  Pos t scoring , the pen/needle will be placed in the pen needle 
disposal fixture .  The pen needle disposal fixtures, along with all used pen needles, 
will be returned to the Sponsor .  
 The Subject  will then inject the subsequent pen/pen needles  into the site according to 
randomization schedule  for a total of six pairs (total of t welve  injections)  
After each pair of injections  
 Subjects will complete a  15 cm relative VAS for injection pain and Likert -scale 
assessment for perceived injection  force  
After all  injections completed  
 Additional survey questions to be completed  

Protocol Number: DBC –18PENDL01  
Version 4.0 25Feb2019  
 
 
BD CONFIDENTIAL    Page 19 of 36 
 
Study staff will follow the same pro cedures for each pen/pen needle set  as noted above . 
 End of Visit and Study Completion  
 The s ubjec ts will be discharged from the S ite following completion of the study procedures, 
when their injection sites show no evidence of bleeding, and when they  are comfortable 
leaving the S ite.  
 Subjects will be instructed to contact [CONTACT_978] [INVESTIGATOR_728668], or 
worsening  signs and symptoms at the injection sites after leaving the Site.  
 All adverse events occurring with S ubjects during the study will be recorded and followed 
until resolution as appropriate.  
7.0 INTERRUPTION OR DISC ONTINUATION OF PARTI CIPATION /TESTING   
 Disconti nuation of Study Subject s 
Subject s may request withdrawal from the study at any time or may be withdrawn at the discretion 
of the Principal Investigator [INVESTIGATOR_225428]:  
 Adverse Event/Concurrent Illness  
 Noncompliance with study requirement s or restrictions  
 Failure to meet ongoing inclusion criteria, or development of an excluding condition  
 Protocol deviation  
 Withdrawal of consent  
 Subject  is lost to follow up  
 Administrative issues  
 Any other reason which, in the opi[INVESTIGATOR_17439], makes the Subject ’s participation in the 
study not in his or her best interest.  
 Discontinuation Visits and Follow -up Procedures  
For Subject s discontinued due to adverse events, the clinical course of the event will be followed 
according to accepted standards of medical practice until the event resolves, stabilizes, or in the 
opi[INVESTIGATOR_689], is no longer considered clinically significant.  
 Replacement of Discontinued Subject s/Specimens  
Recruitme nt of [ADDRESS_995149] s/Specimens  
No data will be collected from Subject s/specimens after the point of discontinuation except as 
needed to follow ongoing adv erse events.  All study data collected from the Subject  up to the 
point of discontinuation will be recorded on the Case Report Form, entered into the study 
database, and included in subsequent analyses, as appropriate.  
Protocol Number: DBC –18PENDL01  
Version 4.0 25Feb2019  
 
 
BD CONFIDENTIAL    Page 20 of 36 
8.0 RISK / BENEF IT ASSESSMENT   
 Potential Risks  
The risks to the Subject  are non -significant and the findings may reveal information that may 
improve medical care for persons with diabetes. The potential benefit to medical practice 
outweighs the non -significant differential risk experienced by [CONTACT_728672]. As a result of inserting a pen needle, Subject s may experience pain, 
bleeding, or local infection. However, given the size of the  investigational  pen needles (4mm x 
32G or smaller ) and the procedures being used in disinfecting the skin and pen devices prior to 
inserting the pen needle , these risks are negligible.  
Risks associated with a pen needle injection may include:  
• Discomfort or pain  
• Fainting  
• Bleeding  
• Bruising  
• Redness  
• Infection  
 Potential Benefits  
There are no direct benefits to the Subject  for participation in this study.  The findings may reveal 
information that will allow for a better understand ing of  pen needle s, and thus may improve 
medical care fo r person s with diabetes . 
9.0 SAFETY  
 Adverse Event Definitions  
Adverse Event (AE):  Any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptom or disease in a Subject  that is temporally associated with the use of an 
investigational product or procedures , even if the event is not considered to be related to the study 
product or procedures.  
This includes events not seen at baseline and events that have worsened if prese nt at baseline.  
The term AE will refer to all adverse events (serious and non -serious) occurring during 
participation in a study of either investigational devices and/or drugs.  
Serious Adverse Event (SAE):  An SAE is any AE occurring during study partici pation that 
results in any of the following outcomes:  
 Death  
 Life Threatening (refers to any event in which the Subject  was at risk of death at the time 
of the event; it does not refer to an event which hypothetically might have caused death if 
it were mor e severe)  
 Hospi[INVESTIGATOR_17127] a hospi[INVESTIGATOR_4408]  
 Persistent or significant disability or incapacitation (refers to any event which results in a 
substantial and/or permanent disruption of the Subject ’s ability to carry out normal life 
functions)  
 Required intervention to prevent permanent impairment/damage  
Protocol Number: DBC –18PENDL01  
Version 4.0 25Feb2019  
 
 
BD CONFIDENTIAL    Page 21 of 36 
 Congenital anomaly/birth defect  
 Important medical event that may require intervention to prevent one of the preceding 
conditions.  
Unanticipated Adverse Device Effect (UADE):  Any serious advers e effect on health or safety 
or any life -threatening problem or death caused by, or associated with, a device, if that effect, 
problem, or death was not previously identified in nature, severity, or degree of incidence in the 
investigational plan or applic ation (including a supplementary plan or application), or any other 
unanticipated serious problem associated with a device that relates to the rights, safety, or welfare 
of Subject s (21CFR -812.3(s) ). Refer to Protocol Section 8.1 (Potential Risks) for a list of 
anticipated  adverse events, signs or symptoms.  
 Adverse Event (AE) Management  
Subject s will be questioned in an open -ended manner throughout the conduct of the study as 
appropriate for any new or worsening undesirable signs or symptoms they may have experience 
since being exposed to the study product. Elicited signs and symptoms must be comprehensively 
documented on the appropriate s ource documentation.  
Each sign, symptom, disease or illness reported must be evaluated by [CONTACT_728673].  
The clinical course of the event will be followed according to accepted standards of medical 
practice until the event resolves, stabilizes, or in the opi[INVESTIGATOR_689], is no longer 
considered clinically significant.  The Investigator must supply the Sponsor with information 
concerning the follow up and/or resolution  of the AE.   
Some reported or observed signs and symptoms are inherent to subcutaneous  injection and are 
likely to occur transiently for nearly all Subject s in this study.   Such signs or symptoms will not be 
considered A Es as long as they are mild (transient , easily tolerated, no interference with daily 
activities ) and the Principal Investigator [INVESTIGATOR_49202].  The following will not be not be considered A Es: 
 Mild, self -limited pain, swelling at the injection site  and presence of wheals  
 Mild bruising at the  injection site  
 Mild self -limited bleeding at the injection site  
 
However, these signs and symptoms must be considered A Es and documented on the Adverse 
Event CRF   should any of them occur in such a way that the extent or nature of the experience 
exceeds that normally associated with the procedure, as judged by [CONTACT_368357], bruising or bleeding.  
All needle breaking  that results in a cannula remai ning in the body either partially or fully,  must 
be considered an AE and documented on the Adverse Event CRF.  
 
 Assessment of Adverse Events (A Es) 
All AEs must be assessed for Seriousness, Severity, and Relationship. All A Es, regardless of 
classification, must be comprehensively documented in the CRF and on the SAE form, if 
applicable, and reported to BD.  This includes A Es related to marketed study products. The 
following information about the event is to be reported on the  AE CRF:  
Protocol Number: DBC –18PENDL01  
Version 4.0 25Feb2019  
 
 
BD CONFIDENTIAL    Page 22 of 36 
 Seriousness, classified as: Non -Serious or Serious  
 Severity,  classified as:  
o Mild: Transient symptoms, easily tolerated, no interference with daily activities  
o Moderate: Marked symptoms, moderate interference with daily activities, tolerable  
o Severe : Considerable interference with daily activities, intolerable  
 Relationship  to the study product or study procedures:  
o Not Related:  Evidence suggests absolutely no possible causal relationship 
between the event and the investigational study device (or procedures).  
o Unlikely Related:  Evidence suggests that other possible causes or contributing 
etiological factors may have caused the event other than the investigational study 
device (or procedures).  
o Possibly Related:  Evidence suggests a causal relationship  between the event and 
the investigational study device (or procedures) cannot be ruled out  
o Related:  Evidence suggests a reasonable causal relationship between the event 
and the device (or procedures) is likely  
In addition, the following should be recorded  for each AE:  
 Action(s) taken to remedy the AE, including change in study treatment or participation, or 
medical/surgical treatments  
 Duration of the AE from onset through resolution, as applicable  
 Cause (including suspected product/procedure and/or other c ause)  
 Outcome of the event, including resolution and sequelae, as applicable  
 Additional Procedures for Assessing & Reporting Serious Adverse Events (SAE)  
SAE criteria are specified in Section 9.1.  All SAEs must also be assessed by [CONTACT_368358]. An adverse 
event will be considered unexpected or unant icipated if the nature, severity or frequency of the 
event is not consistent with the risk information previously described in the protocol, Informed 
Consent, or Investigator’s Brochure (if applicable).  
Any adverse event meeting the criteria for ‘Serious’,  regardless of the Investigator’s opi[INVESTIGATOR_225430], must be reported to BD within [ADDRESS_995150] also submit a completed 
SAE form to the BD Trial Safety Dept. via fax or email listed below within 24 hours  of receipt of 
the information.  
 Safety Email:  BD_T [EMAIL_13886]  
 Safety Fax Line: (US) 1 -[PHONE_4762]  
 
Medical questions about study safety issues and serious adverse events can be directed to 
the Sponsor Medical Monitor . 
9.4.1  Reporting Obligations to IRB/EC and Health Authorities  
The Investigator must report any adverse events which are serious, unanticipated/unexpected 
and probably or possibly related to the study product or procedures to the reviewing IRB/EC.  
Protocol Number: DBC –18PENDL01  
Version 4.[ADDRESS_995151] additional responsibilities for AE reporting to their governing 
Health Authority which they are responsible for identifying and fulfilling.  
The Spons or will provide results of any evaluation of an unanticipated/unexpected adverse 
device effect to appropriate Health Authorities, to all Investigators, and to all reviewing 
IRB/E Cs within 10 working days after the Sponsor is notified of the event.  If the Investigator 
wishes to assume responsibility for filing reports of evaluation results to their own IRB/EC in 
lieu of the Sponsor, they must notify the Sponsor in writing of this preference and must retain 
evidence of their compliance with this requirement.  
BD will comply with all other Sponsor safety reporting requirements and timelines for other 
entities (e.g., Data Safety Monitoring Boards) and local health authorities in other countries 
where this study or other studies with the same product are being co nducted, in compliance 
with study procedures and applicable local regulatory requirements and BD Standard 
Operating Procedures.  
10.[ADDRESS_995152](s), 
reference meth ods, associated procedures or equipment, or represents a product -related injury (or 
potential for injury) to study Subject s or personnel as a result of execution of this protocol.   Clinical Study 
Incidents may adversely (or potentially adversely) affect h uman safety, the integrity of the evaluation 
data, or the operation of devices or systems , and warrant prompt attention.  
Incidents involving injury to study Subject s will also be reported as Adve rse Events (refer to Section 9 ).   
Examples of Clinical Study Incidents that are not Adverse Events might be mislabeling or adulteration 
of the investigational device, equipment or device malfunctions, and errors  in the device 
instructions, damage to devices caused by [CONTACT_11675][INVESTIGATOR_225431] , or injury to 
study personnel due to execution of the protocol .  If appropriate, a n Incident may also be documented 
and reported as a protocol deviation.  
Study -specific p rocedures for reporting Incidents, as well as  adverse events and protocol deviations,  will 
be provided to the study S ite prior to study execution.  The Monitor should be contact[CONTACT_728674]. This includes:  
• Products that are involved in Study Incidents,  
• Products that are found to be expi[INVESTIGATOR_5697], damaged or defective,  
• Products that are possibly the cause of an adverse effect, regardless of whether the product was 
believed to be damaged, defective or malfunctioning.  
Such products (whether investigational or marketed) should be segregated and returned with appropriate 
documentation to the BD address below , unless instructed otherwise by [CONTACT_225447]. The Study Monitor should 
be contact[CONTACT_368362]. BD will supply mailing kits specifically 
intended for product contaminated with potentially bio -hazardous material.  
Protocol Number: DBC –18PENDL01  
Version 4.[ADDRESS_995153]   
Unless instructed otherwise by [CONTACT_225447], the Investigator will return all used  pen needles (secured in the 
provided system) , unused or  unopened  test, reference, and ancillary study products to BD.  At the 
conclusion of the study, and as appropriate during the course of the study, any products, supplies or BD 
equipment that are required to be returned will be shipped to BD at the address below, unless instructed 
otherwise:  
Falguni Patel  
Becton, Dickinson and Company  
[ADDRESS_995154], G334L  
Franklin Lakes, NJ [ZIP_CODE]  
[PHONE_4763]  
 Defective or Failed Study Products  
DFSP: The term DFSP generally refers to any damaged, malfunctioning, or failed product 
(confirmed or suspected) ide ntified at the investigational S ite.  DFSP includes:  
 Products that are involved in Study Incidents,  
 Products that are found to be damaged or defective,  
 Products that fail or malfunction during the study,   
 Study products  rendered unusable due to Subject /patient/S ite S taff mis -use or 
improper storage conditions,  
 Products that are possibly the cause of an adverse effect, regardless of whether the 
product was believed to be damaged, defective or malfunctioning.  
The Monitor  must be contact[CONTACT_728675].  All 
DFSP (whether investigational or marketed) should be segregated and returned with appropriate 
documentation to the BD address above, unless instructed otherwise by [CONTACT_225447]. The Study M onitor 
should be contact[CONTACT_368362]. BD will supply mailing 
kits specifically intended for product contaminated with potentially bio -hazardous material.  
Depending on the intended use of the study products in the  study (e.g., if assessing failure 
modes), there may be exceptions or additions to the requirements for DFSP/Incident 
documentation; these will be described in this protocol or the study -specific Monitoring Plan.  
12.0 DATA COLLECTION AND M ANAGEMENT   
 Source Docu ments  
Source d ata includes all information in original records (and certified copi[INVESTIGATOR_63062] ) of 
clinical findings, observations, or other activities (in a clinical study) used for the reconstruction 
and evaluation of the study. Source data are contained in source documents (original records or 
certified copi[INVESTIGATOR_014]) and are used to verify the authenticity of information recorded on the Case Report 
Form (CRF).  Typi[INVESTIGATOR_368345], medical office file, laboratory 
report, clinician notes, patient record, recorded data from automated instruments or other 
documentation prepared and maintained by [CONTACT_093]/staff or ancillary services which 
contains a record of all observations and other data pertinent to the inves tigation on a study 
Subject .   
Protocol Number: DBC –18PENDL01  
Version 4.0 25Feb2019  
 
 
BD CONFIDENTIAL    Page 25 of 36 
The investigator is required to maintain original source documents at the S ite.  Should an original 
source document (e.g., an instrument printout, direct entry CRF) need to be forwa rded to BD for 
data entry, the S ite must ret ain a clearly designated certified copy.  The Study Monitor will confirm 
that procedures for copy certificatio n have been established at the S ite prior to transmittal of any 
original source documents.   
 Case Report Forms (CRF)  
The case report forms (CRF) will be provided by [CONTACT_1034].  The term “CRF” as used in this 
protocol may refer to traditional paper CRFs, or electronic case report forms for electronic data 
capture (EDC), as determined by [CONTACT_1034].   
The Investigator m ay delegate CRF completion to study personnel.  However, the Sponsor must 
be apprised in writing of the name [CONTACT_225459].  The Principal 
Investigator [INVESTIGATOR_368346], an electronic signature.  An individual record will be kept for each 
Subject  that provided informed consent.  
All entries to a paper CRF should  be made clearly in black or dark blue indelible ballpoint pen to 
ensure  the legibility of self -copying or photocopi[INVESTIGATOR_225435]. Corrections are made by [CONTACT_1299] a 
single horizontal line through the incorrect entry, so that the original entry can still be seen, and 
placing the revised entry beside it. The revised entry must be ini tialed and dated by a member of 
the Investigator ’s research team authorized to make CRF entries. Correction fluid must not be 
used.  
CRF entries will be compared to source documents by [CONTACT_225451]. 
Unless specified otherwise, all information on the CRFs must be traceable to original source 
documents.   
12.2.1  CRF as Source Document  
In this study, the following  CRFs may serve as original source documents:     
 Visual Analog Scale for pain  
 5-Point Likert for injection  force  
 Demographics/ Diabetes History  
 Subject  Questionnaire (s) 
12.2.2  CRF/Data  Transmittal   
Instructions for CRF Trans mittal will be provided to the S ite at Study Initiation. Specific 
procedures may be described in a study -specific Monitoring Plan.    
   
 Data Management and Storage  
Data Management will be performed by [CONTACT_1034].  Data from completed CRFs will be entered 
into a controlled database and the database verified for accuracy against the CRFs, when 
applicable. If electronic data capture is utilized, the ele ctronic records entered at the S ite will be 
entered directly into the controlled database.  Data security is ensured through password 
protection, limited access, audit trails, and regular backups of the data. Upon completion of the 
Protocol Number: DBC –18PENDL01  
Version 4.0 25Feb2019  
 
 
BD CONFIDENTIAL    Page 26 of 36 
study and verification of data, data wil l be screened for accuracy and completeness, after which 
the database will be locked from any additional changes. A copy of the locked database will be 
provided to the GCD  Statistics Department for statistical analysis.  
13.0 STATISTICAL METHODS  
Statistical met hods will be detailed in a Statistical Analysis Plan. Any deviations from the original 
statistical plan will be justified and described in an amended statistical analysis plan and/or the 
protocol, or  in the final statistical report and clinical study report.  
 Sample Size Determination  
Leakage data is currently being used to calculate sample size .   
Based on previous study data (BDT -2P00116) where leakage ≥1.5U was observed in 20/298 
(6.7%) of injections performed with Terumo  Nanopass®  and in 3/297 (1%) of injections performed 
with BD Nano ™ PRO , a simulation was performed (code found in SVN repository under DBC -
18PENDL01 \Stat\Sample Size \ Bayesian prior proportion  R) indicating that 292 injections per 
each pen needle type would provide 90% power to show BD Nano ™ PRO superiority to Terumo 
Nanopass® .  If each Subject  tests 6 pairs of pen needles , 292 injections per each pen needle 
requires 49 subjects (rounded to 50 su bjects).  [ADDRESS_995155] s will generate data for 600 pen needles: 
300 pen needle pairs ; 300 BD Nano ™ PRO  and 300 Terumo Nanopass® .  A 10% buffer was 
added (to compensate for subject attrition or unusable data), leading to a planned enrollment 
number of 55 subjects.  
Pain:  Assuming  the SD for relative VAS is ~ 50mm (based on DBC -17NUCLS07 ), a sample size 
of 300 pairs  ([ADDRESS_995156] s  6 pairs) has >90% power of passing a -10mm NI criteria, assuming a 
true average of -0.5mm in favor of Terumo  Nanopass® (based on a 2-sided 95% CI for the mean).  
 Data Evaluability  
All data collected will be analyzed  and review ed for possible exclusion based on significant 
outliers or protocol deviations.  
Analyses of relative data will only include pairs where both injections were completed.  
 
 Statistical Methods  
Descriptive statistics (number of observations, mean, and standard  deviation, minimum  and 
maximum) will be calculated and presented for all quantitative responses. Frequency tables with 
number of observations, percentage of total and 95% confidence interval (score method) for the 
percentage (as applicable) will be created for discrete responses .  
Analysis for relative VAS pain:  a two-sided 95% confidence interval  will be calculated for the 
average rating.  A modeling approach may be used to adjust for the pair order effect, BD order 
effect  within pair  (due to  the often -observed b ias towards favoring the last pen needle  used  in a 
pair), abdomen site effect and random subject effect .  Results will be tested for non -inferiority, 
followed by [CONTACT_225452] :   
Protocol Number: DBC –18PENDL01  
Version 4.0 25Feb2019  
 
 
BD CONFIDENTIAL    Page 27 of 36 
If the lower bound of the CI is > -10mm, we can conclude in non -inferiority  
If the lower bound of the CI is > 0mm, we can conclude in superiority  
 
Analysis for injection  force via 5-point Likert  scale : the responses will be converted to ratings of -
2 – 2 (where positive ratings favor BD) and a two-sided 95% confidence interval  will be calculat ed 
for the average rating .   A modeling approach may be used to adjust for the pair order effect, BD 
order effect  within pair,  abdomen site effect and random subject effect .  Results will be tested for 
superiority:   
If the lower bound of the CI is > 0, we  can conclude in superiority    
 
Responses will also be converted to 3 categories: favoring Terumo  Nanopass®  (negative 
ratings), no difference (0 ratings) and favoring BD  Nano™ PRO  (positive ratings) and the 
difference in percentage of responses with a pref erence for BD vs Terumo needle calculated , 
adjusting for the “no preference” category .  
 
Analysis for needle  bending and leaking :  analysis will be performed using a binary logistic 
regression with random subject effect and fixed pen needle effect , pair order effect, PN order 
effect within pair  and abdomen site effect. The average difference in percentage of occurrence 
with BD PN and Terumo PN will be calculated with 95% confidence interval and assessed for 
statistical significance.  The upper bound of the  confidence interval will be compared to 0:  
superiority  will be concluded given that the upper bound of the 95% confidence interval for the 
difference in proportions is < 0%. 
 
Analysis for time to deliver  and dwell time :  A mixed effect model will be used (fixed effects of 
pen needle type, abdomen site, order of pair, order of pen needle within pair and random 
Subject  effect) to estimate average difference (BD PN – Terumo PN) in time to deliver  and dwell 
time.  The upper bo und of the confidence interval will be compared to 0:  superiority  will be 
concluded given that the upper bound of the 95% interval for the average difference is < 0 
seconds . 
 
Other e xploratory endpoints will be summarized.  
 
 Demographics/Other descriptive information  
Demographic variables will be summarized for all subject s in each study group. Count, mean, 
standard deviation, median, min, and max values will be calculated for all continuous variables. 
Count and percentage will be calculated for the categorical variables. Subject  disposition will be 
tabulated.  
 
 Safety Analysis  
Data listings will be provided for any adverse event and serious adverse event. Adverse events 
will be summ arized descriptively by [CONTACT_368363] . 
 Interim  analysis  
No interim analysis is  planned  under this protocol . 
Protocol Number: DBC –18PENDL01  
Version 4.[ADDRESS_995157] obtained 
written IRB/ EC approval (as required) for participation in this study, who have completed all 
required study documentation, and who have been qualified  by [CONTACT_1034].  Investigators must 
maintain control over all study products, and ensure they are used in accordance with this 
protocol.  Failure to do so may result in the Sponsor suspending or terminating t he study at the 
Investigator’s S ite.   
The Inve stigator will ensure that study products are only dispensed to Subject s (or used for 
specimens) properly enrolled in the study. The Investigator must maintain records of receipt, 
disposition, return and/or destruction  of all study products. All investigati onal study products 
released to the S ite must be accounted for at the unit level prior to study close out, regardless of 
disposition.  The Study M onitor will regularly review all records regarding study product 
accountability.  
The Sponsor will maintain re cords that document the shipment, receipt, disposition, return and /or 
destruction of study products.  
 Monitoring  
BD, the study sponsor, will designate trained and qualified personnel to monitor the progress of 
this clinical study in accordance with BD Mon itoring SOPs and the study -specific Monitoring Plan.  
A pre -study S ite qualification visit will be conducted  to assess the adequacy of the S ite facilities 
and staff with respect to study requirements.  
Prior to study start, a study initiation visit will be  conducted to provide training to Site S taff with 
regard to the protocol, the completion of study documentation and Case Report Forms (CRFs), 
the monitoring schedule, and all regulatory requirements. During the study, routine monitoring 
visits w ill be cond ucted to assure the S ite continues to adhere to the protocol, the investigator 
agreement, and regulations regarding conduct of clinical studie s.  Assessments will be made 
regarding the Subject s’ protection and safety, when relevant, as well as the quality, completeness, 
and integrity of the data. The Study Monitor will assist the investigative Site with query resolution 
and will perform Site close -out activities once all queries have been resol ved. 
Additional visits may  be carried out depending upon S ite activity and performance. The 
Investigator must agree to the inspection of all study related records and give direct access to 
source documents for verification of data on CRFs.  
The Investigato r is responsible for ensuring that any Site-owned equipment required for use in 
the study is properly installed and maintained (e.g., inspected, calibrated, alarmed). 
Documentation of equipment maintenance procedures must be available for review by [CONTACT_179648].   
 Audits and Inspections  
If the study is selected for audit by [CONTACT_368364], then the Investigator and his team will make themselves available during the 
Protocol Number: DBC –18PENDL01  
Version 4.[ADDRESS_995158] agree to the inspection of all study related records and give the 
auditor/inspector direct access to source documents for verification of data on CRFs.  The 
Subject ’s anonymity must be safeguarded and data checked during the audit remain confidential.  
As soon as the Investigator is aware of an upcoming inspection/audit by [CONTACT_217928], 
he/she will promptly inform BD.  As agreed with the Investigator, BD p ersonnel may be present 
at the S ite during the inspection.   
 Protocol Deviations  
Protocol devia tions are not permitted and should be implemented prospectively as a protocol 
amendment whenever practical or appropriate, unless required to protect the safety and well -
being of the Subject .  The Investigator must notify the Sponsor immediately of any suc h deviation 
resulting from the need to protect a Subject .   
Protocol deviations (other than those required to protect the safety and well -being of a Subject ) 
may impact the evaluability of study data, and may place Subject s at risk.   If the Investigator o r 
their staff inadvertently deviates from the study plan, the Investigator should implement 
appropriate corrective and preventive procedures, and should notify the Sponsor at their earliest 
convenience.  Significant deviations may also need to be reported to the IRB/ EC and local health 
authority.   
The Study Monitor will evaluate r ecords of study conduct at the S ite to identify any deviations, 
and will also report them to the Sponsor.  Upon evaluation by [CONTACT_1034], actions may be 
required to prevent additional deviations, such as retraining of the Site, implementation of 
additional Site procedures, and more frequent monitoring.  If these steps fail, more se rious 
measures, up to and including termination of the Site and withdrawal of study product may be 
necessary.   
15.0 ETHICA L AND  REGULATORY S TANDARDS   
 IRB/EC  
An appropriate IRB/ EC must review this protocol, the Informed Consent Form  (if applicable) , and 
any ot her supporting study documents which affect Subject  or study personnel safety, prior to 
study initiation at an investigational Site. No investigational Site may begin the study until the 
IRB/EC has given its written approval, signed by [CONTACT_1201]/ EC chairpers on or authorized personnel, 
and a copy of the approval letter and the approved Informed Consent Form (if applicable) has 
been provided to the Sponsor.  
 Informed Consent  
Prior to giving informed consent, each candidate will have the opportunity to review the study 
procedures, risks and benefits and ask any questions he or she may have regarding the study. 
Before enrollment , each Subject  must give informed consent, document ed by [CONTACT_2960] a written 
form, created and approved in compliance with [ADDRESS_995159]  confidentiality and anonymity 
Protocol Number: DBC –18PENDL01  
Version 4.[ADDRESS_995160] party without the express written consent of the 
Principal Investigator [INVESTIGATOR_1238]/or Site.  
The Study Monitor or other authorized representatives of BD may inspect all documents and 
records required to be maintained by [CONTACT_737].  The Site will permit access to such records.   
BD and the Site may be required to provide regulatory agencies access to clinical study  data and 
records, as well as source documents.  
All other agreements as to confidentiality by [CONTACT_225447], the Pr incipal Investigator, and the Site may be 
found in the Confidential Disclosure Agreement and the Clinical Trial Agreement.  
 Protocol Modifications   
Amendments to the protocol will not be implemented without agreement from the Sponsor and 
prior submission to  and written approval from the governing IRB/ EC, except when necessary to 
eliminate an immediate hazard to the Subject . Notice of an emergency modification shall be given 
to the Sponsor and the reviewing IRB /EC as soon as possible, but in no event later th an [ADDRESS_995161] s. 
Minor changes to the protocol, such as correction of typographical errors or changes in personnel 
names (other than the P I) or contact [CONTACT_117856]. 
Administrative changes will be submitted to the governing IRB/ EC but implementation of the 
administrative change may proceed without prior IRB/EC approval, unles s so required by [CONTACT_5040]/EC or S ite SOPs .  
 Study Discontinuation  
BD reserves the right to temporarily suspend or prematurely dis continue the study at a single S ite 
or at all Sites at any time and for any reason.  If such action is taken, BD will discuss the reasons 
with all Inves tigators (the Investigator).  If the study is terminated or suspended due to safety 
reasons, the Sponsor  will inform the health authorities as required, and provide the reason(s) for 
the action.  Investigator(s) must inform their IRB/ EC promptly and provid e the reason(s) for the 
suspension or termination.  
 Clinical Study  Registration   
In compliance with Title VIII of Public Law [ADDRESS_995162] of 2007 
(FDAAA), BD will register all applicable studies and disclose study results in a publicl y accessible 
database, e.g. the Clinical Trials .gov web site.  Applicable studies will be registered no later than 
[ADDRESS_995163]  visit for collection of primary outcome data, or after 
health authority approval for previously unapproved devices.  BD has responsibility for 
determining whether this study qualifies as an “applicable” study  under the law, and if so, will take 
responsibi lity for registration and disclosure as required by [CONTACT_2371].  
Protocol Number: DBC –18PENDL01  
Version 4.0 25Feb2019  
 
 
BD CONFIDENTIAL    Page 31 of 36 
 Publication of Results   
BD believes that results of applicable clinical studies  of our products should be published in peer -
reviewed literature in a timely, accurate, complete and balanced manner, re gardless of study  
outcomes. BD is committed to making information public whenever it relates to the safety and 
efficacy of its marketed products.  
Any formal presentation or publication of data collected from this study will be considered as a 
joint publica tion by [CONTACT_093](s) and the appropriate personnel of BD. Authorship will be 
based on generally accepted criteria of the ICMJE (International Committee of Medical Journal 
Editors) and determined by [CONTACT_11402]. For multi -center studies, the fir st publication will 
be based on data from all centers, analyzed as stipulated in the protocol by [CONTACT_225453], and 
not based on data from  a single Site or a subset of Sites. Investigators participating in multi -center 
studies agree not to present data gathered from one center or a small group of centers before the 
full, initial publication, unless formally agreed to by [CONTACT_225454] (the sole 
exception being an unanticipated adverse event that is product -related and which might have 
clinically significant safety implications for a marketed product or a class of products).  
BD must receive copi[INVESTIGATOR_368347]. In a timely manner, BD will review the comm unications for accuracy 
(thus avoiding potential discrepancies with submissions to health authorities), verify that 
confidential information is not being inadvertently divulged and to provide any relevant 
supplementary information to the investigators.  
 Record Retention  
If the Principal Investigator [INVESTIGATOR_368348], custody must be transferred to a person or entity who will accept the responsibility.  
BD must be notified in writing of the name  [CONTACT_1640].  
Federal regulations require that a copy of all essential study documents (e.g., IRB/ EC approvals, 
signed informed consent forms, source documents, CRF copi[INVESTIGATOR_014], safety reports, test article 
dispensing records, etc.), must b e retained in the files of the responsible Investigator for a 
minimum of 2 years following notification by [CONTACT_225455], terminated, 
or discontinued, or that the FDA has approved the application (21 CFR 812.140).  
16.0 BIBLIOGRAPHY/RE FERENCES  
1. Edwards CL, Fillingim RB, Keefe F. Race, ethnicity and pain.  Pain.  2001; 94:133 -137. 
2. Watson PJ, Latif RK, Rowbotham DJ. Ethnic differences in thermal pain responses: a 
comparison of South Asian and White British healthy males.  Pain. 2005;118:[ADDRESS_995164] South 
Asian minority ethnic groups in the [LOCATION_006].  Rheumatology.  2007; 46:1009 -1014  
4. O Komiyama, M Kawara, A De Laat.  Ethnic differences regarding tactile and pain thresholds in 
the trigeminal region.  The Journal of Pain . 2007; 8(4): 363 -369. 
5. Mieko M.  Beliefs about appropriate pain behavior: cross ‐cultural and sex differences between 
Japanese and Euro ‐Americans, European Jr Pain . 2012; 9(4): 389 -393. 
Protocol Number: DBC –18PENDL01  
Version 4.0 25Feb2019  
 
 
BD CONFIDENTIAL    Page 32 of 36 
17.0 PROTOCO L REVISION HISTORY  
Version #  Rationale for Change  Section or 
Page affected  Description of change   
1.0 New Protocol    
2.0 Clarified Leakage collection 
when blood is at the injection 
site 
 
 
 
 
 
 
 
Corrected typo of TM in title  Section 6.2.1  
 
 
Section 13.2 
 
 
Section 18.6  Updated language to insure leakage was 
collected from PN tip, if there was blood 
at injection site  
 
Removed that if blood was observed that 
the sample would not be included in the 
data analysis  
 
Updated leakage procedure  
3.0  Sutter Health has safety 
concerns on re -using the 
ClikSTAR ® Insulin Reusable 
Pen for more than one subject .  Section 5.0  
and 
Section  6.2.1  
 A new ClikSTAR® Insulin Reusable Pen 
will be used for each subject.  
4.[ADDRESS_995165] with e ither a new or 
cleaned ClikSTAR® Insulin 
Reusable Pen 
 
 Section 1.[ADDRESS_995166] or 
pharmacy.  
 
 
Either a new or cleaned ClikSTAR® 
Insulin Reusable Pen will be used for 
each subject  depending on site  
preference . See Appendix 18.3 for Pen 
Cleaning Procedure)  
 
 
Protocol Number: DBC –18PENDL01  
Version 4.0 25Feb2019  
 
 
BD CONFIDENTIAL    Page 33 of 36 
Version #  Rationale for Change  Section or 
Page affected  Description of change   
Clarified  the two times that Site 
Staff will record during needle 
injection  
 
 
 
 
 
Updated introduction to cleaning 
procedure section   
 
 
Update Medical Affairs 
signature [CONTACT_728679] 6.2.1  
 
 
 
Section 16.0  
 
Section 16.3  
 
 
Sponsor 
Approval 
Section  Total injection time will be recorded by 
[CONTACT_112806].  The time from injection button 
fully depressed to the removal of needle 
from body will be calculated by [CONTACT_728676].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol Number: DBC –18PENDL01  
Version 4.0 25Feb2019  
 
 
BD CONFIDENTIAL    Page 34 of 36 
 
18.0 APPENDICES  
18.1: Gravimetric Leakage Quantification Procedure  
 
Quantification of Liquid from Pen Needle and Skin Surface after Administration  
 
Study Staff preparing and handling plastic tubes and eye spears must do so with gloved hands to 
prevent transfer of oils from hands to the assembly. Tubes are to be pre -weighe d in the morning 
of the day of use.  
 
Materials:  
• Cellulose Spears  
• Analytical Balance  minimally accurate to 0.000 gm  
• Plastic Falcon tubes (to hold spears)  
 
Procedure:  
1. Label (number) a set of plastic tubes.   
2. Arrange empty, uncapped tubes in test -tube rack and place one spear in each tube, replace 
caps securely on tubes.   
3. Zero the Balance.  Balance should be placed in an area with limited activity to avoid vibration.  
4. Pre-weigh tube with spear by [CONTACT_368365] (resting on its cap). Tubes will be 
pre-weighed in the morning of the day of use.  
5. Record the dry weight on the appropriate data collection form (pre (dry) -weight).  
6. Collect fluid from skin  and needle tip using the pre -weighed absorbent sp ear.  Do not collect 
fluid from skin if bleeding  
7. Immediately replace spear into tube, replace cap securely and as soon as possible weigh the 
tube by [CONTACT_368366] (resting on its cap ) or place in pre -weighed beaker . 
8. Record wet weight on t he data collection form (post (wet) -weight).  
9. Discard tube with eye spear.  
  
 
  
Protocol Number: DBC –18PENDL01  
Version 4.[ADDRESS_995167] bend scoring, pen needle will be disposed of as 
appropriate.   
Cannula bend scal e (exampl e): 
 
 
Degree of Bend  Score  
0° (no bend)  0 
> 0° to 10°  1 
>10° to 20°  2 
> 20° to 30°  3 
> 30° to 40°  4 
> 40° 5 
 
  

Protocol Number: DBC –18PENDL01  
Version 4.[ADDRESS_995168] with the patient’s hands.   The pens will be cleaned using the procedure described below 
after each use using hospi[INVESTIGATOR_728669] -base d disinfectant wipes.   Any pens contaminated with blood 
will not be re -used and will be discarded in the appropriate container for destruction.  
 
 The following cleaning procedure will be performed by [CONTACT_728677]:  
 Cleaning the pens  is to be completed using hospi[INVESTIGATOR_368350]  
 Gloves should be worn while completing this cleaning procedure  
 Clean the pens by [CONTACT_100411][INVESTIGATOR_368351] . Care is to be exerted that 
no lint or other particles are l eft behind during the process.  
o Use fresh disinfectant wipe for each pen. Discard wipe after each use.  
o Air dry the pens for about one minute .  
 
 
 
 
 